Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04884477
Other study ID # 21-001374
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 1, 2021
Est. completion date January 15, 2023

Study information

Verified date February 2023
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is being conducted to determine if patients with compromised B-cell function due to anti-CD20 therapy and newly diagnosed COVID-19 infection benefit from convalescent plasma.


Description:

This is a retrospective cohort study comparing patients, with newly diagnosed COVID-19 infection, previously treated with anti-CD20 drugs for diseases including vasculitis or hematologic malignancy, who are given high titer convalescent plasma with similar patients receiving usual care that does not include convalescent plasma. The goals are: 1. To describe the natural course of COVID-19 in patients previously treated with anti-CD20 drugs for diseases such as vasculitis and hematologic malignancies. The investigators' hypothesis is that patients who acquire COVID-19 preceded by recent anti-CD20 therapy develop a prolonged course of COVID-19 infection which is not improved by remdesivir and immunomodulator agents alone. 2. To quantify the risk for each outcome among patients with COVID-19 according to the time they had received anti-CD20 therapy. The hypothesis is that patients with COVID-19 may be less responsive to COVID-19 directed therapy when anti-CD20 was given more recently (e.g., less than 6 months) prior to contracting COVID-19. 3. To compare the outcome of patients with COVID-19 who have received anti-CD20 drugs and are treated or not with high titer convalescent plasma sufficient to reach passive seroconversion. The hypothesis is that patients who have received an anti-CD20 drug within the previous 6 months of their COVID-19 diagnosis have a reduced chance of achieving a full recovery without first reaching passive SARS-CoV2 seroconversion. Data will be extracted from a data registry, built in the electronic health record (EHR) environment, automatically logging subjects based on data in the electronic health record and extracting relevant data metrics. This is put into a data mart nightly via an extract, transform and load process used as part of routine operations and validated as part of routine maintenance. Metric definitions in the registry system include validation of data as being within defined limits based on the entry of EHR values to prevent outliers inconsistent with reasonable data. The registry is built in the medical record system, and is checked for consistency as part of the EHR architecture and maintenance. All data is extracted from the Epic electronic health record. Diagnoses and procedures are coded using ICD-10-CM and SNOMED-CT and laboratory data identified using appropriate LOINC codes. Rules based metrics calculate demographic information and risks scores such as the Charlson comorbidity index, as indicated in the attached data dictionary. Outcome analyses will be subjected to propensity score (PS) adjustment to account for non-random treatment selection. First, the investigators will estimate the PS from a multivariable logistic regression in which predictors of receiving CP (within the first 30 days) are determined as a function of patient baseline characteristics. The propensity model will include age, sex, race, APACHE-3 score, and additional baseline covariates chosen a priori based on clinical relevance. Finally, comparison of the CP and no CP treatment outcomes will be adjusted for baseline differences by including PS (as restricted cubic spline in the logit PS to allow for nonlinear effects) in the outcome regression model with the CP treatment variable. As an additional PS technique, patients treated without CP will be matched to patients who received CP based on disease group (vasculitis or hematologic malignancy) and propensity score within a tolerance of 0.2 standard deviations of logit-PS. To avoid survival bias, the matching process will consider only the eligible controls who were followed as long or longer than the time-to-first transfusion of the CP case. Separate proportional odds logistic regression models will be fitted for the univariate WHO ordinal outcome score at 30 days and for multivariate outcome scores at 30, 60 and 90 days (as a repeated measures analysis), with the patients' CP status, time, baseline WHO score, and PS included as independent variables. ICU-free days, defined as the number of days alive and free of ICU between study entry and day 30 or day 90 will be calculated and compared between CP and no CP groups using Poisson regression. For this analysis, the investigators will initially start all patients at time of positive PCR in the no CP group. When patients receive their first transfusion, their non-CP follow-up will be truncated, and their follow-up will be restarted at time zero in the CP group. The investigators will use an offset in the model to allow for difference in observation days between the two groups. Lastly, treatment heterogeneity will be explored for pre-specified baseline characteristics (e.g., time since anti-CD20, sex, race) by testing treatment-by-covariate interactions in the outcome models. Time since anti-CD20 will be analyzed as a continuous variable using an expanded cohort to consider a wider range of times (within 3 years). The investigators will also examine the association between time since anti-CD20 use and study outcomes, irrespective of plasma treatment. Again, time will be considered on a continuum and modeled flexibly using regression splines to allow for nonlinear relationships with the outcome. Sensitivity analyses: Stratification by category of disease (vasculitis vs. hematologic malignancies) and stratification by titer of antibodies, seroconversion achieved, time (from initial positive PCR) when plasma was given.


Recruitment information / eligibility

Status Completed
Enrollment 342
Est. completion date January 15, 2023
Est. primary completion date January 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of COVID-19 infection - Positive SARS CoV2 PCR - Enrolled in the Mayo Clinic COVID-19 registry - History of treatment with anti-CD20 drugs within past 3 years Exclusion Criteria: - Patients who declined to have their chart reviewed for research purpose. - Patients who have received convalescent plasma within the previous 3 months of COVID-19 diagnosis - Patients who have received monoclonal antibodies that target SARS-CoV-2 in the past three months

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Convalescent Plasma
Convalescent Plasma

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in WHO Clinical Progression scale In this observational study examining the use of convalescent plasma (CP) for treatment of CD20-depleted patients with COVID-19, we will describe the clinical course of these patients and conduct a comparative treatment analysis. "Time zero" will be considered the date the patient first tested positive for COVID-19, and the time-dependent nature of CP transfusion will be explicitly used in the analysis. The primary outcome of interest is the WHO ordinal outcome score measured repeatedly over 90-day follow-up. The WHO ordinal scale for Clinical Improvement ranges from 0 uninfected to 8 for Dead. Lower scores are seen with better clinical outcomes. 90 days
Secondary 90-day mortality "Time zero" will be considered the date the patient first tested positive for COVID-19, and the time-dependent nature of CP transfusion will be explicitly used in the analysis. The first secondary outcome will be 90-day mortality. 90 days
Secondary ICU-free days The number of days the patient spent at home or in the hospital not in the ICU will be counted over the 90 days following the date the patient first tested positive for COVID-19, and following convalescent plasma transfusion 90 days
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure

External Links